Solid Tumors | CHOP Research Institute
 

Solid Tumors

This study involves taking a study drug called INBRX-109.

This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and RET fusion.

This study involves an investigational cellular therapy called Afamitresgene Autoleucel.

The Grupp Lab works to develop new molecular-based targeted cancer treatments and cell-based immunotherapies to treat leukemia and solid tumors. The team aims to develop advanced cancer treatments that are less toxic than existing therapies to treat children with high-risk malignancies.

This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose.

This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment.

This study involves a taking a study drug called vactosertib by mouth.

This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion.

The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations.

Published on
Sep 15, 2023
CHOP scientists share their expertise in circadian research and SMA treatments. This and more this week’s news.